Sampson, J. H., Vlahovic, G., Desjardins, A., Friedman, H. S., Baehring, J. M., Hafler, D., … Reardon, D. A. (2014). Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). In Journal of Clinical Oncology (Vol. 32, pp. TPS2101–TPS2101). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101

Sampson, John Howard, Gordana Vlahovic, Annick Desjardins, Henry S. Friedman, Joachim M. Baehring, David Hafler, Linda Rollin, Vlad Coric, Susan N. Perez, and David A. Reardon. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2101–TPS2101. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101.

Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, et al. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS2101–TPS2101.

Sampson, John Howard, et al. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. TPS2101–TPS2101. Crossref, doi:10.1200/jco.2014.32.15_suppl.tps2101.

Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, Rollin L, Coric V, Perez SN, Reardon DA. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS2101–TPS2101.